Chuanzhen Cao Zhichao Fu Yueping Liu Aiping Zhou Jianfei Wang Jianzhong Shou
10.3389/fimmu.2021.684879
Front Immunol
2021 Jun 10;12:684879.
bladder-sparing chemotherapy immunotherapy muscle-invasive bladder cancer next-generation sequencing
CC BY
https://pubmed.ncbi.nlm.nih.gov/34177933/
Carcinoma, Transitional Cell / therapy Muscle Neoplasms / therapy Retinoblastoma Binding Proteins / genetics Ubiquitin-Protein Ligases / genetics Urinary Bladder Neoplasms / therapy
Carcinoma, Transitional Cell / therapy Muscle Neoplasms / therapy Retinoblastoma Binding Proteins / genetics Ubiquitin-Protein Ligases / genetics Urinary Bladder Neoplasms / therapy Case Reports Antibodies, Monoclonal, Humanized Carcinoma, Transitional Cell / genetics Carcinoma, Transitional Cell / pathology Chemoradiotherapy Humans Immunotherapy Male Middle Aged Muscle Neoplasms / secondary Mutation Neoadjuvant Therapy Remission Induction Treatment Outcome Urinary Bladder Neoplasms / genetics Urinary Bladder Neoplasms / pathology Antibodies, Monoclonal, Humanized RB1 protein, human Retinoblastoma Binding Proteins pembrolizumab Ubiquitin-Protein Ligases
PMC8222973
34177933
A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report
2021